Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.
Consulting agreement: €104,000 annual compensation, plus options for 15,000 shares at Nasdaq closing price on July 1, 2024, vesting quarterly over 3 years.
Schellens brings 25+ years oncology experience, former CMO at Byondis B.V., board member of Dutch Medicines Evaluation Board.
He will lead clinical trial oversight, regulatory strategy, and serve as primary medical monitor.
Agreement provides for services 2 days per week, based in Netherlands; term until terminated by either party with 60 days' notice.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jan Schellens

Chief Medical Officer

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Filed: June 5, 2024, 7:59 PM ET

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.6

Jan Schellens was appointed as Chief Medical Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

View on SEC.gov

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-022709

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.